Background: SARS-CoV-2 breakthrough infections (BI) after vaccine booster dose are a relevant public health issue. Methods: Multicentric longitudinal cohort study within the ORCHESTRA project, involving 63,516 health workers (HW) from 14 European settings. The study investigated the cumulative incidence of SARS-CoV-2 BI after booster dose and its correlation with age, sex, job title, previous infection, and time since third dose. Results: 13,093 (20.6%) BI were observed. The cumulative incidence of BI was higher in women and in HW aged < 50 years, but nearly halved after 60 years. Nurses experienced the highest BI incidence, and administrative staff experienced the lowest. The BI incidence was higher in immunosuppressed HW (28.6%) vs others (24.9%). When controlling for gender, age, job title and infection before booster, heterologous vaccination reduced BI incidence with respect to the BNT162b2 mRNA vaccine [Odds Ratio (OR) 0.69, 95% CI 0.63-0.76]. Previous infection protected against asymptomatic infection [Relative Risk Ratio (RRR) of recent infection vs no infection 0.53, 95% CI 0.23-1.20] and even more against symptomatic infections [RRR 0.11, 95% CI 0.05-0.25]. Symptomatic infections increased from 70.5% in HW receiving the booster dose since < 64 days to 86.2% when time elapsed was > 130 days. Conclusions: The risk of BI after booster is significantly reduced by previous infection, heterologous vaccination, and older ages. Immunosuppression is relevant for increased BI incidence. Time elapsed from booster affects BI severity, confirming the public health usefulness of booster. Further research should focus on BI trend after 4th dose and its relationship with time variables across the epidemics.

BackgroundSARS-CoV-2 breakthrough infections (BI) after vaccine booster dose are a relevant public health issue.MethodsMulticentric longitudinal cohort study within the ORCHESTRA project, involving 63,516 health workers (HW) from 14 European settings. The study investigated the cumulative incidence of SARS-CoV-2 BI after booster dose and its correlation with age, sex, job title, previous infection, and time since third dose.Results13,093 (20.6%) BI were observed. The cumulative incidence of BI was higher in women and in HW aged < 50 years, but nearly halved after 60 years. Nurses experienced the highest BI incidence, and administrative staff experienced the lowest. The BI incidence was higher in immunosuppressed HW (28.6%) vs others (24.9%). When controlling for gender, age, job title and infection before booster, heterologous vaccination reduced BI incidence with respect to the BNT162b2 mRNA vaccine [Odds Ratio (OR) 0.69, 95% CI 0.63-0.76]. Previous infection protected against asymptomatic infection [Relative Risk Ratio (RRR) of recent infection vs no infection 0.53, 95% CI 0.23-1.20] and even more against symptomatic infections [RRR 0.11, 95% CI 0.05-0.25]. Symptomatic infections increased from 70.5% in HW receiving the booster dose since < 64 days to 86.2% when time elapsed was > 130 days.ConclusionsThe risk of BI after booster is significantly reduced by previous infection, heterologous vaccination, and older ages. Immunosuppression is relevant for increased BI incidence. Time elapsed from booster affects BI severity, confirming the public health usefulness of booster. Further research should focus on BI trend after 4th dose and its relationship with time variables across the epidemics.

Incidence and Determinants of Symptomatic and Asymptomatic SARS-CoV-2 Breakthrough Infections After Booster Dose in a Large European Multicentric Cohort of Health Workers-ORCHESTRA Project / Porru, Stefano; Monaco, Maria Grazia Lourdes; Spiteri, Gianluca; Carta, Angela; Caliskan, Gulser; Violán, Concepción; Torán-Monserrat, Pere; Vimercati, Luigi; Tafuri, Silvio; Boffetta, Paolo; Violante, Francesco Saverio; Sala, Emma; Sansone, Emanuele; Gobba, Fabriziomaria; Casolari, Loretta; Wieser, Andreas; Janke, Christian; Tardon, Adonina; Rodriguez-Suarez, Marta Maria; Liviero, Filippo; Scapellato, Maria Luisa; Dell'Omo, Marco; Murgia, Nicola; Mates, Dana; Calota, Violeta Claudia; Strhársky, Jozef; Mrázová, Mariana; Pira, Enrico; Godono, Alessandro; Magnano, Greta Camilla; Negro, Corrado; Verlato, Giuseppe. - In: JOURNAL OF EPIDEMIOLOGY AND GLOBAL HEALTH. - ISSN 2210-6014. - 13:3(2023), pp. 1-12. [10.1007/s44197-023-00139-8]

Incidence and Determinants of Symptomatic and Asymptomatic SARS-CoV-2 Breakthrough Infections After Booster Dose in a Large European Multicentric Cohort of Health Workers-ORCHESTRA Project

Gobba, Fabriziomaria;
2023

Abstract

BackgroundSARS-CoV-2 breakthrough infections (BI) after vaccine booster dose are a relevant public health issue.MethodsMulticentric longitudinal cohort study within the ORCHESTRA project, involving 63,516 health workers (HW) from 14 European settings. The study investigated the cumulative incidence of SARS-CoV-2 BI after booster dose and its correlation with age, sex, job title, previous infection, and time since third dose.Results13,093 (20.6%) BI were observed. The cumulative incidence of BI was higher in women and in HW aged < 50 years, but nearly halved after 60 years. Nurses experienced the highest BI incidence, and administrative staff experienced the lowest. The BI incidence was higher in immunosuppressed HW (28.6%) vs others (24.9%). When controlling for gender, age, job title and infection before booster, heterologous vaccination reduced BI incidence with respect to the BNT162b2 mRNA vaccine [Odds Ratio (OR) 0.69, 95% CI 0.63-0.76]. Previous infection protected against asymptomatic infection [Relative Risk Ratio (RRR) of recent infection vs no infection 0.53, 95% CI 0.23-1.20] and even more against symptomatic infections [RRR 0.11, 95% CI 0.05-0.25]. Symptomatic infections increased from 70.5% in HW receiving the booster dose since < 64 days to 86.2% when time elapsed was > 130 days.ConclusionsThe risk of BI after booster is significantly reduced by previous infection, heterologous vaccination, and older ages. Immunosuppression is relevant for increased BI incidence. Time elapsed from booster affects BI severity, confirming the public health usefulness of booster. Further research should focus on BI trend after 4th dose and its relationship with time variables across the epidemics.
2023
13
3
1
12
Incidence and Determinants of Symptomatic and Asymptomatic SARS-CoV-2 Breakthrough Infections After Booster Dose in a Large European Multicentric Cohort of Health Workers-ORCHESTRA Project / Porru, Stefano; Monaco, Maria Grazia Lourdes; Spiteri, Gianluca; Carta, Angela; Caliskan, Gulser; Violán, Concepción; Torán-Monserrat, Pere; Vimercati, Luigi; Tafuri, Silvio; Boffetta, Paolo; Violante, Francesco Saverio; Sala, Emma; Sansone, Emanuele; Gobba, Fabriziomaria; Casolari, Loretta; Wieser, Andreas; Janke, Christian; Tardon, Adonina; Rodriguez-Suarez, Marta Maria; Liviero, Filippo; Scapellato, Maria Luisa; Dell'Omo, Marco; Murgia, Nicola; Mates, Dana; Calota, Violeta Claudia; Strhársky, Jozef; Mrázová, Mariana; Pira, Enrico; Godono, Alessandro; Magnano, Greta Camilla; Negro, Corrado; Verlato, Giuseppe. - In: JOURNAL OF EPIDEMIOLOGY AND GLOBAL HEALTH. - ISSN 2210-6014. - 13:3(2023), pp. 1-12. [10.1007/s44197-023-00139-8]
Porru, Stefano; Monaco, Maria Grazia Lourdes; Spiteri, Gianluca; Carta, Angela; Caliskan, Gulser; Violán, Concepción; Torán-Monserrat, Pere; Vimercati, Luigi; Tafuri, Silvio; Boffetta, Paolo; Violante, Francesco Saverio; Sala, Emma; Sansone, Emanuele; Gobba, Fabriziomaria; Casolari, Loretta; Wieser, Andreas; Janke, Christian; Tardon, Adonina; Rodriguez-Suarez, Marta Maria; Liviero, Filippo; Scapellato, Maria Luisa; Dell'Omo, Marco; Murgia, Nicola; Mates, Dana; Calota, Violeta Claudia; Strhársky, Jozef; Mrázová, Mariana; Pira, Enrico; Godono, Alessandro; Magnano, Greta Camilla; Negro, Corrado; Verlato, Giuseppe
File in questo prodotto:
File Dimensione Formato  
s44197-023-00139-8.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 1.77 MB
Formato Adobe PDF
1.77 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1312150
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact